Overview

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Atorvastatin
Atorvastatin Calcium
Torcetrapib